newsfilter.io
Interview

The Challenges Behind the COVID-19 Vaccines Rollout

Goldman SachsVeronika Dubajova, Veronica, Liz
Watch on YouTube →

Scale and Scope of Vaccine Distribution

  • The U.S. adult population (~250 million) requires approximately 500 million doses, a volume nearly three times the annual U.S. flu vaccine market of 160–180 million.
  • Global vaccination targets involve 5 billion adults, requiring a total of 10 billion doses to complete two-dose regimens.
  • Logistical challenges are bifurcated into upstream supply constraints and downstream distribution logistics.

Upstream Supply Challenges

  • Vials: The industry requires 2–3 billion additional glass vials to support the global target; this is achievable as current annual production capacity is ~10 billion vials and most vaccines are formulated for 5–6 doses per vial.
  • Syringes and Needles: A 1:1 ratio is required for administration (10 billion units total), a demand that has been partially offset by significant lead-time investment and manufacturing scaling since May 2020.
  • Inventory Status: No critical upstream shortages are currently anticipated for vials or syringes given the 8-month development lead time prior to rollout.

Downstream Logistics and Storage

  • Cold Chain Requirements:
    • Pfizer-BioNTech: Originally required storage at -70°C (-95°F); capacity to remain out of freezing for 5 days has been achieved, up from an initial 1-day limit.
    • Moderna: Requires storage at -20°C, which is significantly more manageable than ultra-cold requirements.
    • AstraZeneca/Oxford: Approved in the UK for storage at standard refrigeration temperatures (2–8°C).
  • Emerging Markets: The availability of vaccines requiring standard refrigeration (AstraZeneca) and improved stability for existing formulations (Pfizer/Moderna) facilitates broader distribution in regions with limited infrastructure.
  • Administrative Bottlenecks: In the U.S., 25 million doses have been shipped while only ~15 million have been administered, leaving ~10 million doses unutilized.
  • Coordination Friction: Delays stem from a complex supply chain (Federal → State → Hospital → Provider) and anecdotal instances where hospital demand exceeds supply capacity.

Supply Allocation and Demand Dynamics

  • Second-Dose Reservations: Governments held back portions of the initial supply to ensure second-dose availability, as efficacy relies on two doses from the same manufacturer; this stock is being released to increase throughput.
  • Initial Target Priorities: Rollout prioritizes hospital workers, followed by community healthcare workers, and then individuals over 65 with comorbidities.
  • Vaccination Hesitancy: Surveys of 15 U.S. hospital administrators indicate only 30–50% of frontline staff expressed willingness to be vaccinated, likely driven by caution among women of childbearing age and populations of color.
  • Public Willingness: Broader population surveys estimate 50–60% willingness to vaccinate, a figure expected to rise as more safety data becomes available and the benefits of vaccination are realized.

Forward-Looking Statements

  • Pediatric Development: Clinical trials for children are ongoing; data is not expected until later in the year, though adult vaccination remains the immediate priority given the strong correlation between age/comorbidities and severe disease outcomes.
  • Demand Projection: Goldman Sachs Research expects vaccination demand to increase over time as the pool of vaccinated individuals grows and public confidence solidifies.
  • Supply Release: The release of withheld second-dose supplies is anticipated to immediately alleviate current bottlenecks in the U.S. distribution network.